4 research outputs found
Recommended from our members
Design prototyping methods
textProduct development is often modeled as a cycle between phases of designing, building, and testing. This work will explore early stage build efforts of product design, which is also known as prototyping. Prototyping is a critical determinant of product success. Research shows that different approaches to prototyping can greatly affect design outcome. This work provides an integrated overview, and expansion of the existing work on design prototyping methods. Following the introduction, an extensive literature review of design prototyping tools, techniques, and methods is provided. These sources are indexed and comparatively reviewed. The capabilities of a novel hybrid prototyping technique is explored through a design case study. Next, insights from the review are integrated in a context independent prototyping strategy method. The method is developed with heuristics extracted from the literature, and additional insights from experimental studies. The technique is then experimentally evaluated. Finally, results of an extensive study of an online design repository are provided. The results include five key principles for prototype design and fabrication. The presence of these principles in the repository is validated through a novel crowd-sourced online study. The outcome effects of deploying these principles to design teams is experimentally evaluated. Overall, this research provides a guide to prototyping which includes a systematically indexed review and comparison of the existing work, as well as a novel method, and principles for design and fabrication.Mechanical Engineerin
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Background:
Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings:
Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79).
Interpretation:
In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background:
In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings:
Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).
Interpretation:
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Recommended from our members
Transformational indicators : deciding when to develop transformable products
textTransformable products (or transformers), those with two or more functional states, are increasingly utilized by our society. As the mobility and complexity of life increases, so must the adaptability of the products which we use. We need new design techniques to develop more adaptable devices, such as transformers. The purpose of this study is to propose a response to the question “When is it preferable to implement a design approach focused on developing transformable products over an approach focused on developing primary function, non transforming products?” Our response to this question comes in the form of a method. The method helps a designer or design team consider the benefits of developing a transformer at an early stage in the design process. Research includes a deductive and an inductive study which are used to identify transformation indicators or context properties and usage factors that identify when it is preferable to build a transformable device. Static function-state indicators are also presented. These are contrary to transformation indicators in that they identify contexts suitable for developing non-transforming devices. Our technique seeks to improve the outcome of a design project by encouraging the consideration of transformable solutions and aiding in the selection of an appropriate design process. This method for testing the presence of these indicators in exemplary design contexts is presented. One such application is the design of an autonomous bridge-health monitoring system.Mechanical Engineerin